ReviewInternational journal of environmental research and public health2018
Statins and Cardiovascular Disease Outcomes in Chronic Kidney Disease: Reaffirmation vs. Repudiation.
Review in International journal of environmental research and public health, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- Chronic kidney disease and cardiovascular risk: Pathophysiology and interventional approaches - systematic review.Medicine · 2025Pooled it
- Uremic Serum Alters Gene Expression Profiles and Signaling Pathway Activity in Porcine Arterial Smooth Muscle Cells.Biomolecules · 2026Article
- Impaired Kidney Function, Subclinical Myocardial Injury, and Their Joint Associations with Cardiovascular Mortality in the General Population.Journal of clinical medicine · 2025Article
- Endothelial dysfunction in chronic kidney disease: a clinical perspective.American journal of physiology. Heart and circulatory physiology · 2025Review
- Prognostic value of HALP score in predicting in-hospital mortality in patients with NSTEMI.Biomarkers in medicine · 2025Article
- Coronaries, Calcium, and Kidney Consequences.Kidney international reports · 2024Article
- Di-(2-ethylhexyl) Phthalate Limits the Lipid-Lowering Effects of Simvastatin by Promoting Protein Degradation of Low-Density Lipoprotein Receptor: Role of PPARγ-PCSK9 and LXRα-IDOL Signaling Pathways.Antioxidants (Basel, Switzerland) · 2023Article
- Atherosclerosis Specific Features in Chronic Kidney Disease (CKD).Biomedicines · 2022Review
- Association of Renal Arteriosclerosis With Atherosclerotic Cardiovascular Disease Risk in Lupus Nephritis.Arthritis care & research · 2022Article
- Mass Spectrometry-Based Lipidomics Reveals Differential Changes in the Accumulated Lipid Classes in Chronic Kidney Disease.Metabolites · 2021Article
- Renal Function-Dependent Associations of Statins with Outcomes of Ischemic Stroke.Journal of atherosclerosis and thrombosis · 2021Article
- Review
- Acute Coronary Syndromes in Chronic Kidney Disease: Clinical and Therapeutic Characteristics.Medicina (Kaunas, Lithuania) · 2020Article
- The impact of dyslipidemia and oxidative stress on vasoactive mediators in patients with renal dysfunction.International urology and nephrology · 2019Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Cardiovascular disease (CVD) burden is several-fold higher in patients with chronic kidney disease (CKD). Although statins have been shown to provide significant CVD benefits in both the general population and patients with CKD, this has not translated into survival advantage in patients with advanced CKD or on dialysis. It has been reported that CVD risk continues to escalate as CKD progresses to end-stage kidney disease (ESKD); however, the CVD risk reduction by statins appears to decline as patients' progress from the early to later stages of CKD. Statins have also been associated with a higher incidence of stroke in ESKD patients. Thus, the CVD benefits of statins in ESKD remain questionable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.